The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A randomised, open, phase IV, parallel group multicentre study to evaluate a change of management in Gastroesophageal Reflux Disease (GERD) patients by treatment with esomeprazole 40 mg or any other Proton Pump Inhibitor (PPI), after initial treatment failure, in ordinary clinical practice during 4 weeks.
- collapse An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients with Symptoms of Gastroesophageal Reflux Disease (GERD) to Investigate the Relationship between the Presence of Erosive Esophagitis (EE) at Baseline and Heartburn Resolution after 4 Weeks of Treatment
- collapse An Open-Label, 2-way Crossover Study of Steady-state Intragastric pH Control Comparing 2 Dosage Regimens of Esomeprazole and Lansoprazole in Barrett’s Esophagus Patients
- collapse A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of the 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects on Days 1 and 5 of Intravenous Treatment
- collapse HEARD (Long Term) Study
- collapse A Randomized, Open-Label, Comparative, Two-Treatment, Crossover Study of the 24-Hour Intragastric pH Profile after 5 Days of Once Daily Oral Administration of either Esomeprazole 40 mg or Pantoprazole 40 mg following Once Daily Infusion of Intrazenous Pantoprazole 40 mg for 5 Days in Healthy Volunteer Subjects
- collapse Acid Perfusion Heartburn Study
- collapse A Randomized, Open-Label, Comparative 3-way Treatment Crossover Study of 24-hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in NSAID-using Patients.
- collapse A Multicenter, Double-blind, Randomised Trial of the Intagastric Acid Control and Healing Effects of Esomeprazole Magnesium 10mg and 40mg Once Daily (NEXIUM) in the Treatment of Moderate and Severe Erosive Esophagitis (LA Classification Grades C & D).
